Cisatracurium dose–response relationship in patients with chronic liver disease  by Ali, Mohamed Z. et al.
Egyptian Journal of Anaesthesia (2014) 30, 197–202Egyptian Society of Anesthesiologists
Egyptian Journal of Anaesthesia
www.elsevier.com/locate/egja
www.sciencedirect.comResearch ArticleCisatracurium dose–response relationship
in patients with chronic liver disease* Corresponding author. Tel.: +20 1111113115; fax: +20 235408125.
E-mail addresses: zeidanoma@hotmail.com, zeidanoma@yahoo.com
(M.Z. Ali).
Peer review under responsibility of Egyptian Society of Anesthesiol-
ogists.
Production and hosting by Elsevier
1110-1849 ª 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists.
Open access under CC BY-NC-ND license. http://dx.doi.org/10.1016/j.egja.2013.10.007
Open access under CC BY-NC-NMohamed Z. Ali a,*, Reeham S. Ebied a, Maha A. Atallah a, Hossam H. El Sabea a,
Amr Abd El Monaem b, Mounis A. Abo-Sedira a, Inas Kamel ba Department of Anesthesia, Theodor Bilharz Research Institute, Giza, Egypt
b Department of Anesthesia, Faculty of Medicine, Cairo University, Cairo, EgyptReceived 2 August 2013; revised 8 October 2013; accepted 27 October 2013
Available online 23 November 2013KEYWORDS
Cisatracurium;
Dose–response curve;
Chronic liver diseaseAbstract Objective: Cisatracurium is approximately 3 times more potent than atracurium, devoid
of histamine release and cardiovascular side effects and mainly eliminated by Hofmann degrada-
tion. Patients with liver disease exhibit abnormal response to most of muscle relaxants. This study
was designed to evaluate the dose–response of cisatracurium in patients with mild–moderate liver
impairment in comparison with healthy subjects.
Methods: Eighty ASA physical status I–II patients of both sexes, scheduled for elective surgical
procedures under general anesthesia, were divided according to their preoperative hepatic status
and laboratory investigations into two groups; Group I (control group with normal liver functions,
n= 40) and Group II (Liver dysfunction group, Child-Pugh Score A or B, n= 40). The dose–
response curve was constructed, ED50 and ED95 were estimated.
Results: The preoperative laboratory parameters showed statistically signiﬁcant differences
between the two groups regarding serum albumin, total bilirubin, ALT, AST, PT, PC and INR.
The operative data showed statistically insigniﬁcant difference between the two groups regarding
the 1st dose response (p= 0.152), the estimated ED80 (p= 0.886) and the calculated 2nd dose
(p= 0.886) and statistically signiﬁcant differences between the two groups regarding the 2nd dose
response (p= 0.006), the measured ED50 (p= 0.010) and the measured ED95 (p= 0.001). In con-
clusion, the measured ED50 and ED95 through two-dose dose–response curve technique were clin-
ically insigniﬁcant from using the single-dose technique. The dose–response curve of cisatracurium
in patients with chronic liver disease was clinically insigniﬁcant in comparison with healthy subjects.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists.D license.1. Introduction
Introduction of skeletal muscle relaxants into clinical anesthe-
sia practice has not only made general anesthesia (GA) more
effective but also allowed sophisticated techniques to be
accomplished. The use of muscle relaxants in controlled
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extend its use in the intensive care unit. Since the ﬁrst use of
Curare, many muscle relaxants have been discovered and stud-
ied in an attempt to meet the requirements of an ideal muscle
relaxant [1].
Cisatracurium was found to be approximately three times
more potent than atracurium, with no histamine release or
cardiovascular side effects. The duration of action is about
45–50 min compared to atracurium which is 35–40 min [2].
Hofmann degradation has a greater role in the elimination
of cisatracurium than that of atracurium [3].
Patients with chronic liver disease exhibit an abnormal re-
sponse to the effect of most of muscle relaxants. The expanded
extracellular ﬂuid compartment leads to increase in volume of
distribution of the highly ionized neuromuscular blockers.
Hence an apparent resistance is usually observed in the form
of increased dose requirement which when administered may
last longer due to the associated delayed elimination in this
group of patients [4,5].
The dose–response curves could be used to plot the results
of many kinds of experiments. The X-axis plots concentration
of a drug (dose). The Y-axis is the response. The shape of
dose–response curves depends on which drug is used and
which response is measured as in Fig. 1. The standard dose–
response curves is deﬁned by four parameters: the base
response (Bottom), the maximum response (Top), the Slope
and the Concentration that provokes a response half-way
between the baseline and the maximum (EC50) [6].
2. Subjects and methods
This study was approved by the Theodor Bilharz Research
Institute Ethical Committee. All patients provided written
informed consents. This prospective observational study
included 80 ASA physical status I–II adult patients of both
sexes scheduled for elective general surgical or urological pro-
cedures under general anesthesia. Elderly, morbidly obese,
pregnant patients and those with malignancies were excluded.
Also patients receiving drugs affecting neuromuscular blockers
as anticonvulsants, antihistaminics, antibiotics, diuretics and
antidepressants were excluded.
Patients were allocated into one of two equal groups
according to their preoperative hepatic status and laboratory
investigations; Group I (control group, with normal liver
functions, n= 40) and Group II (Liver dysfunction group,
Child-Pugh Score A or B, n= 40) (Table 1).
All the patients were assessed preoperatively regarding liver
function tests (serum total bilirubin, total proteins, albumin
and glubulins, AST, ALT, Alkaline phosphatase, prothrombinFigure 1 The dose–time and concentration and INR), kidney function tests (blood
urea and serum creatinine), fasting blood glucose and complete
blood count.
Standard continuous monitoring including 5-lead ECG,
NIBP, SpO2, PETCO2 and anesthesia gas analyzing system
(Dra¨ger inﬁnity Kappa, Dra¨ger Medical Corporation,
Germany) was attached to all patient. Neuromuscular
monitoring using TOF-Guard (INMT Organon Teknika
NV-Belgium) was also used.
Without any premedication, preoxygenation with 100% O2
was administered via face mask before induction of anesthesia
for at least ﬁve deep breaths. Anesthesia was then induced
using I.V. fentanyl 2 lg kg1 and I.V. 2.5% thiopentone so-
dium 5–7 mg kg1.
Patients were then ventilated manually via facemask with
isoﬂurane 1% (end-tidal concentration) in O2: Air mixture
(FiO2 = 0.6) for 3 min. A Laryngeal Mask Airway Classic
(LMA, Intavent Orthoﬁx, Maidenhead, UK) was then
inserted (size 3 for females and 4 for males). Ventilation
was assisted or controlled to maintain normocapnia
(PETCO2 = 36–40 mmHg). Anesthesia was then maintained
with the same gaseous mixture plus fentanyl 50 lg I.V. incre-
ments given as clinically indicated.
While hemodynamic stability was achieved, the ulnar nerve
was stimulated supramaximally at the wrist with square pulses
of 0.2 m s duration; delivered in a train-of-four (TOF)
sequence at 2 Hz repeated every 15 s. An acceleration Piezo-
electric transducer was fastened to the volar surface of the
distal phalanx of the thumb contralateral to the site of I.V.
infusion. The arm was immobilized in splint. Free movement
during evoked thumb adduction was ensured by ﬁxation of
the extended four ulnar ﬁngers by an elastic bandage or adhe-
sive tape. Registration of evoked thumb acceleration, in
response to adductor pollicis contractions was carried out
using TOF-Guard. After calibration of TOF-Guard device
and a stable TOF-response for a minimum of 3–5 min was
reached, the study was started and all information were
derived from acceleration transducer recorded on a memory
card and subsequently a computer print-out was obtained
using TOF-Guard reader software.
According to the method recommended by Kopman et al.
(to get the dose–response curve from two doses), a small initial
dose (10 lg kg1) of cisatracurium was given and the neuro-
muscular blockade was monitored and recorded until no
further change is observed. This would constitute the 1st
dose–response point. This value used to draw the patient‘s
measured dose response curve, from that curve the estimated
ED80 was identiﬁed. The difference between the 1st dose which
already given to the patient and the estimated ED80 wouldresponse curves.
Table 1 Child-Pugh Score.
Measure 1 Point 2 Points 3 Points
Total bilirubin, lmol/l (mg/dl) <34 (<2) 34–50 (2–3) >50 (>3)
Serum albumin, g/l >35 28–35 <28
PT INR <1.7 1.7–2.3 >2.3
Ascites None Mild Moderate to Severe
Hepatic encephalopathy None Grade I–II (or suppressed with medications) Grade III–IV (or refractory)
Points Class One year survival Two year survival
5–6 A 100% 85%
7–9 B 81% 57%
10–15 C 45% 35%
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administered should produce 80% blockade.
Following the administration of the supplemental dose, the
neuromuscular response was observed until maximum block
was achieved. This would constitute the second dose–response
point. From the two dose–response points the dose–response
curve was constructed (knowing that the slopes of all muscle
relaxants are nearly identical and equal to 4.75). This formed
the two-dose dose–response curve for each individual. From
that curve the ED50 and ED95 for each individual was
estimated. The ED50 and ED95 for each group of subject were
calculated and statistically analyzed.
After completing the study, tracheal intubation and
controlled mechanical ventilation was achieved. At the end
of surgery, reversal of the neuromuscular blockade was estab-
lished and the patient was extubated.
Preoperative laboratory parameters in addition to 1st dose–
response (degree of suppression), estimated ED80, calculated
2nd dose, 2nd dose–response (degree of suppression), mea-
sured ED50 and measured ED95 were recorded in both groups.
2.1. Statistical methods
Data were analyzed using SPSS version 15 (SPSS Inc., Chi-
cago, IL). Numerical data were expressed as mean ± standard
deviation (Mean ± SD). Qualitative data were expressed as
frequency and percentage. Chi-square test (Fisher’s exact test)
was used to examine the relation between qualitative variables.
For quantitative data, comparison between two groups was
done using independent sample t-test. A p-value < 0.05 was
considered signiﬁcant.
3. Results
There was no statistical signiﬁcant difference between the two
study groups regarding demographic data (Table 2).Table 2 Patients’ characteristics in the two groups of the study.
Variables Control group (n= 40)
Age (yrs) 43.9 ± 11.3
Weight (kg) 81.7 ± 16.6
Gender (male/female) 24/16
ASA physical status (I/II) 21/19
Data are expressed as mean ± SD, numbers NS = not signiﬁcant.Regarding the preoperative laboratory parameters (Table 3),
there was no signiﬁcant difference between the two groups
regarding the levels of hemoglobin concentration
(p= 0.534), fasting blood glucose (p= 0.276), blood urea
(p= 0.525), serum creatinine (p= 0.819) and total plasma
proteins (p= 0.135). However, there were statistical signiﬁ-
cant differences between the two groups regarding serum albu-
min concentration (p= 0.001), total bilirubin level
(p= 0.001), ALT (p= 0.001), AST (p= 0.001), PT
(p= 0.001) PC (p= 0.001), and INR (p= 0.001).
There was no statistical signiﬁcant difference between the
two groups regarding the 1st dose response (degree of suppres-
sion) which ranges from 5.75% to 6.65% in the hepatic and con-
trol groups, respectively (p= 0.152). Similarly, the estimated
ED80 was comparable in the two groups; 15.13–16.59 lg kg
1
in the control group and 15.13–16.98 lg kg1 in the hepatic
group (p= 0.886). The calculated 2nd dose in the control group
(5.13–6.59 lg kg1) was not signiﬁcantly different from that of
the hepatic group (5.13–6.98 lg kg1) (p= 0.886).
However, the measured response to the calculated 2nd dose
was signiﬁcantly higher in the control group (32.00–
46.00 lg kg1) than the hepatic group (32.00–42.00 lg kg1)
(p= 0.006). The measured ED50 (15.13–21.39 lg kg
1) in the
hepatic group was signiﬁcantly higher than the corresponding
values in the control group (16.59–21.37 lg kg1) (p= 0.010).
The measured ED95 (57.54–100 lg kg
1) in the hepatic group
was signiﬁcantly higher than the corresponding values in
the control group (31.62–79.43 lg kg1) (p= 0.001\).
Table 4 and Figs. 2–4 show the operative variables in the study
groups.4. Discussion
Results of the present study demonstrates no signiﬁcant differ-
ence in the degree of suppression produced by the ﬁrst dose of
cisatracurium in liver disease patients compared to controlPatient group (n= 40) p Value
48.3 ± 11.3 0.226NS
87.9 ± 14.1 0.210NS
21/19 0.327NS
23/17 0.519NS
Table 3 Preoperative laboratory parameters in the two groups of the study.
Variables Control group (n= 40) Patient group (n= 40) p Value
Hb (g/dl) 12.5 ± 2.0 12.1 ± 1.3 0.534NS
Fasting blood glucose (mg/dl) 88.7 ± 15.7 84.4 ± 7.1 0.276NS
Blood urea (mg/dl) 25.4 ± 6.2 26.6 ± 6.2 0.525NS
Serum creatinine (mg/dl) 1.3 ± 0.2 1.2 ± 0.2 0.819NS
Serum total bilirubin (mg/dl) 1.2 ± 0.2 2.0 ± 0.5 0.001\
Serum total proteins (g/dl) 7.5 ± 0.5 7.3 ± 0.4 0.135NS
Serum albumin (g/dl) 4.5 ± 0.6 3.4 ± 0.4 0.001\
SGOT (AST) (IU/L) 29.5 ± 6.1 75.2 ± 13.5 0.001\
SGPT (ALT) (IU/L) 34.0 ± 6.3 84.1 ± 14.7 0.001\
Prothrombin time (s) 12.3 ± 0.9 18.0 ± 1.3 0.001\
Prothrombin concentration (%) 88.0 ± 5.0 57.5 ± 7.6 0.001\
International normalized ratio 1.1 ± 0.1 1.7 ± 0.3 0.001\
Data expressed as mean ± SD. NS = not signiﬁcant; \ = signiﬁcant.
Figure 2 The measured dose response curve of the control
group.
Figure 3 The measured dose response curve of the hepatic
group.
Figure 4 Comparison between the measured dose response curve
of the group versus the hepatic group.
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ond dose was signiﬁcantly lower in liver disease patients
(p= 0.006). The dose response curve showed minor difference
in the estimated ED80 between patients and controls, and sig-
niﬁcantly higher ED50 and ED95 in liver disease patients
(p= 0.010 and p= 0.001, respectively).The liver plays an important role in the pharmacokinetics
of neuromuscular blocking drugs regarding the offset of the
block. Patients with liver disease show prolonged duration of
action which depends on the character and severity of liver dis-
ease and is attributed to prolonged elimination half-life result-
ing from reduced plasma clearance and increased volume of
distribution due to increase extracellular ﬂuid [7]. Atracurium
and cisatracurium seem to be favorable exceptions because of
their unique breakdown mechanism. However, the elimination
half-life of their potentially toxic metabolites in patients with
severe liver disease is decelerated [8].
Cisatracurium undergoes spontaneous degradation in the
body at physiological pH and temperature by organ-indepen-
dent Hofmann elimination to form laudanosine and a mono
quaternary acrylate metabolite that undergoes hydrolysis by
non-speciﬁc plasma esterases to form a mono quaternary alco-
hol. Hydrolysis of cisatracurium by plasma esterases is not an
important pathway for elimination of cisatracurium [3]. In
contrast, atracurium is eliminated by Hofmann degradation
and hydrolysis by non-speciﬁc esterases [9,10].
Although the liver seems to play only a minor part in the
elimination of cisatracurium, it is a primary pathway for the
elimination of its metabolites [10]. These metabolites, however,
do not possess neuromuscular blocking activity, but laudano-
sine can be harmful [11].
Table 4 Operative data in the two groups of the study.
Variables Control group (n= 40) Patient group (n= 40) p Value
1st Dose response (degree of suppression) (%) 6.7 ± 1.8 5.8 ± 2.1 0.152NS
Estimated ED80 (lg kg
1) 16.0 ± 0.4 16.0 ± 0.4 0.886NS
Calculated 2nd dose (lg kg1) 6.0 ± 0.4 6.0 ± 0.4 0.886NS
2nd Dose response (degree of suppression) (%) 38.0 ± 2.9 35.5 ± 2.5 0.006\
Measured ED50 (lg kg
1) 18.4 ± 1.0 19.4 ± 1.3 0.010\
Measured ED95 (lg kg
1) 51.0 ± 0.9 73.6 ± 11.4 0.001\
Data expressed as mean ± SD. NS = not signiﬁcant; \ = signiﬁcant.
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requirements and subsequently laudanosine concentration
are less, therefore the safety margin of the drug is greater espe-
cially if given by infusion [12].
In a study of 14 patients with end-stage liver disease sched-
uled for liver transplantation, after a single bolus of cisatracu-
rium, small increases in volume of distribution (21%) and
clearance (16%) have been found with no difference in its elim-
ination half-life or change in its recovery proﬁle and no appar-
ent effect of liver disease on its urinary excretion [13].
A pharmacokinetic single-dose study comparing children
with normal hepatic function with those awaiting liver trans-
plantation showed no differences in atracurium pharmacoki-
netics [14].
Bergeron et al. [15] reported that the clinical duration (time
to 25% twitch recovery) of the 0.15 mg kg1 dose of cisatrac-
urium was 59 min. This ﬁgure was comparable to the 55 min
reported by Bluestein et al. [16] at the same dose and under
similar anesthetic conditions.
From continuous infusions of atracurium used during liver
transplantation, it appeared that the rate of atracurium infu-
sion required during liver transplantation was not different
from that in patients with normal hepatic function [17]. Con-
versely, Cammu et al. [18] reported that cisatracurium dose
requirements during liver transplantation tended to be higher
than reported infusion rates of cisatracurium in healthy sub-
jects (1.4 lg kg1 min1).
In most pharmakokinetic–pharmakodynamic studies for
cisatracurium, isoﬂurane was used as the anesthetic agent.
During these conditions, administration of a 0.1 mg kg1 bo-
lus dose of cisatracurium resulted in a mean EC50 value of
98 ng ml1 [13,19]. This low EC50 value is in agreement with
the known potentiating effect of isoﬂurane. When propofol
was used as the anesthetic agent the mean EC50 value derived
after a 5-min infusion of a 0.1-mg kg1 dose of cisatracurium
was 153 ng ml1 [15,20].
In the current study, after a total dose of 0.119 mg kg1, the
ED50 was 18.4 lg kg
1 in control group and 19.4 lg kg1 in li-
ver disease group. The difference was clinically insigniﬁcant.
Using the single-dose method, Dahaba et al. [21] reported an
ED50 of 28 lg kg
1. Others reported ED50 of 29 lg kg
1 [22],
30 lg kg1 [23], and 31.1 lg kg1 [24].
Similarly, we found that ED95 of the control group
50.9 lg kg1 which is comparable to 55.3 lg kg1 reported
by Dahaba et al., [21] and 48 lg kg1, 53 lg kg1, and
57.6 lg kg1 reported by previously mentioned authors,
respectively [22–24].
Bergeron et al. [15] proved the dose dependency of the EC50
of cisatracurium through pharmacokinetics and pharmacody-
namics study. As cisatracurium pharmacokinetics proved tobe linear, the dose-related changes observed in the pharmaco-
dynamic parameters cannot be of pharmacokinetic origin. A
15% decrease in the dose-normalized ECmax and a 30% in-
crease in tECmax were observed at the highest dose.
Cammu et al. [18] proposed that in continuous infusion of
cisatracurium during liver transplantation, the tendency to-
ward higher dose requirements, the protracted duration of
infusion, the non-Hofmann elimination and/or other pharma-
cokinetic changes during transplantation might inﬂuence
recovery from the neuromuscular block.
In this study, it was found that there was no effect on liver
disease on dose response to cisatracurium apart from a
statistically and clinically signiﬁcant higher ED95 (73.6 lg kg
1
versus 50.99 lg kg1 in the control group).
Liver disease does not appear to have an effect on the uri-
nary excretion of cisatracurium [13]. Similar ﬁndings have been
published for atracurium. In fact, renal clearance and renal
elimination of unchanged drug may be slightly greater for
cisatracurium than for atracurium [25–27]. This may be related
to the fact that atracurium contains short-acting isomers that
are less likely to appear in the urine [13].5. Conclusion
Use of cisatracurium as a neuromuscular blocking agent in
patients with chronic liver disease seems to be favorable and
safe. Liver disease does not appear to have an effect on dose
response to cisatracurium through study of dose response
curve.
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